Eylea Post Marketing Surveillance(PMS)

• Status: Completed
• Trial end date: 2018-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this PMS is to gain information about safety and efficacy in real practice as a regulatory commitment required by MFDS

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Collaborator: Regeneron Pharmaceuticals
• Treatments: Aflibercept

Criteria

Inclusion Criteria:

• Patients determined to start EYLEA treatment

• Patients who agree and sign informed consent

• Patients who receive EYLEA treatment for the first time

• Patients who meet one of the following

• Patients diagnosed by physician as having neovascular (wet) age-related macular degeneration wAMD

• Patients diagnosed by physician as having visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO)

• Patients diagnosed as having visual impairment due to diabetic macular edema (DME)

• Patients diagnosed as having visual impairment due to myopic choroidal neovascularization (mCNV)

Exclusion Criteria:

• Patients who have received anti-VEGF therapy within 90 days

• Patients who are contraindicated based on the approved product label

• Ocular or periocular infection

• Active severe intraocular inflammation

• Known hypersensitivity to any ingredient of this drug